

COLIFOAM

10% hydrocortisone acetate

FIRST CLASS TREATMENT WHICH TRAVELS TO WORK

- Colifoam is highly effective for distal ulcerative colitis.⁽¹⁾
- The retrograde spread of Colifoam increases with the extent of disease.⁽²⁾
- Colifoam is easier to retain than liquid enemas and causes less interference with social, sexual and occupational activities.^(1,3)

COLIFOAM

PRESCRIBED WITH CONFIDENCE FOR OVER 20 YEARS.

PRESCRIBING INFORMATION: **Presentation:** White odourless aerosol containing hydrocortisone acetate PhEur 10% w/w. **Uses:** Ulcerative colitis, proctosigmoiditis and granular proctitis. **Dosage and administration:** One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed with pack). **Contra-indications, warnings etc:** Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety

during pregnancy has not been fully established. Although uncommon at this dosage, local irritation may occur. **Pharmaceutical precautions:** Pressurised container containing flammable propellant. Protect from sunlight and do not expose to temperatures above 50°C. Keep away from sources of ignition. Do not pierce or burn even after use. Do not refrigerate, store below 25°C. Keep out of reach of children. For external use only. **Legal category:** POM. **Package quantity & basic NHS cost:** 20.8g canister plus applicator, £7.07. Provides approximately 14 doses. **Product Licence no:** 0036/0021. **References:** 1. Somerville KW *et al.* BMJ 1985;291:866. 2. Farthing MJG *et al.* BMJ 1979;2:822-824. 3. Ruddell WSJ *et al.* Gut 1980;21:885-889. Further information is available on request from Stafford-Miller Ltd., Broadwater Road, Welwyn Garden City, Herts. AL7 3SP. **Code:** D02665.

EVERYDAY PEOPLE TAKE LOSEC.

Losec offers efficacy, flexibility, practicality and good tolerability. And with over 190 million treatments in 96 countries, it also inspires a high level of confidence. No wonder Losec is taking care of more people. Every day.



LOSEC[®]
(omeprazole-Astra)

**THE CONFIDENCE TO TAKE CARE OF
MORE PEOPLE. EVERY DAY.**

LOSEC[®] CAPSULES (omeprazole) PRESCRIBING INFORMATION (refer to full data sheet before prescribing)

PRESENTATION: Losec Capsules containing 10mg, 20mg or 40mg omeprazole (O) as enteric coated granules with an aqueous based coating. **USES:** Oesophageal reflux disease. Duodenal and benign gastric ulcers (including NSAID-induced). Prophylaxis of NSAID-associated ulcers in patients with a history of gastroduodenal lesions, including relief of dyspeptic symptoms. *Helicobacter pylori* eradication: Relief of associated dyspeptic symptoms in combination treatment with antibiotics. Prophylaxis of acid aspiration. Zollinger-Ellison syndrome. **DOSAGE & ADMINISTRATION: Adults (including the elderly):** The usual dose in oesophageal reflux disease and peptic ulcer is 20mg once daily, increasing to 40mg once daily in severe or refractory cases, if required. **Oesophageal reflux disease:** Healing: 20mg daily for 4 weeks. Continue for further 4-8 weeks if required. **Maintenance in acid reflux disease:** Losec 10mg daily. Increase to 20mg daily if symptoms return. **Duodenal ulcer (DU):** Healing: 20mg daily for 4 weeks. **DU maintenance:** Losec 10mg daily increasing to 20mg daily if symptoms return. **Benign Gastric Ulcer:** 20mg daily for 8 weeks. **Prophylaxis of NSAID-associated DU & GU:** Losec 20mg once daily. **Helicobacter pylori eradication: DU disease: Triple therapies:** Losec 40mg daily with amoxicillin (A) 500mg and metronidazole (M) 400mg, both three times a day for 1 week. Or clarithromycin (C) 250mg and metronidazole 400mg (or tinidazole 500mg) both bd for

1 week. Or amoxicillin 1g and clarithromycin 500mg both bd for 1 week. **Dual therapies:** Losec 40mg daily with amoxicillin 750mg to 1g bd or clarithromycin 500mg tid, both for 2 weeks. **GU disease:** Losec 40mg daily with amoxicillin 750mg to 1g bd for 2 weeks. **Prophylaxis of acid aspiration:** Losec 40mg on the evening before surgery followed by Losec 40mg on the morning of surgery. **Zollinger-Ellison Syndrome:** 60mg daily as long as clinically indicated. Individually adjust within range 20-120mg daily. If in excess of 80mg daily give in 2 equal divided doses. **Renal impairment:** No dose adjustment needed. **Hepatic impairment:** Adjust dose (maximum daily dose 20mg). **Children:** No experience of use. **CONTRA-INDICATIONS, WARNINGS, etc:** Known hypersensitivity to omeprazole. In gastric ulcer, exclude malignancy before starting therapy. Avoid in pregnancy unless no safer alternative. Discontinue breast feeding if Losec is considered essential. **Side effects:** Losec is well tolerated. Adverse reactions are generally mild and reversible (relationship to Losec not established in many cases). They include diarrhoea, headaches, skin disorders and in isolated cases, angioedema, musculoskeletal disorders, fatigue, insomnia, dizziness, blurred vision, dry mouth, vertigo, paraesthesia, anaphylaxis, liver enzyme and haematological changes. **Interactions:** The absorption of ketoconazole may be reduced. Losec can delay the elimination of diazepam, phenytoin and warfarin. Plasma concentrations of omeprazole and clarithromycin are increased when used concomitantly. Simultaneous treatment with omeprazole and digoxin may

increase the bioavailability of digoxin. **PHARMACEUTICAL PRECAUTIONS:** Store below 30°C. Bottles: Use within three months of opening. Replace cap firmly after use. Dispense in original container. **LEGAL CATEGORY:** POM. **FURTHER INFORMATION:** *Helicobacter pylori* (Hp) is associated with acid peptic and ulcer disease, contributing to gastritis and ulcer recurrence. Eradication of Hp with omeprazole and antibiotics gives rapid symptom relief, high healing rates and long-term remission of ulcer disease.

Quality of life. In recent clinical data, in patients with acute peptic ulcer disease, omeprazole Hp eradication therapy improved patients' quality of life. **PACKAGE QUANTITIES:** 10mg: bottles of 7* capsules £4.99, bottles of 28 capsules £19.95. 20mg: bottles of 7* capsules £8.86, bottles of 28 capsules £35.45. 40mg: bottles of 7* capsules £17.72, blisters of 7 capsules £17.72. (*Hospital pack only). **MARKETING AUTHORIZATION NO:** PL 0017/0337 - Losec Capsules 10mg. PL 0017/0238 - Losec Capsules 20mg. PL 0017/0320 - Losec Capsules 40mg.

ASTRA
Astra Pharmaceuticals

For further information contact the **MARKETING AUTHORIZATION HOLDER:** Astra Pharmaceuticals Ltd, Home Park, Kings Langley, Herts WD4 8DH. Tel: (01923) 266191.

LOSEC is a registered trademark of Astra Pharmaceuticals Ltd.

Date of preparation: November 1996

LOS/ADV 1552



FAST • STRONG • LONG LASTING

GAVISCON

ADVANCE

IMPROVED FORMULA

Gaviskon Advance Prescribing Information. Gaviskon Advance. Active ingredients: Sodium alginate BP 1000mg and potassium bicarbonate USP 200mg per 10ml dose. **Indications:** Gastric reflux, reflux oesophagitis, heartburn, hiatus hernia,

flatulence associated with gastric reflux, heartburn of pregnancy, all cases of epigastric and retrosternal distress where the underlying cause is gastric reflux. **Dosage and Administration:** Adults and children over 12: 5-10ml liquid, after meals

and at bedtime. Children under 12: Only on medical advice. **Contra-indication:** Hypersensitivity to any of the ingredients. **Precautions and warnings:** 10ml liquid contains 4.6mmol (106mg) sodium and 2.0mmol (78mg) potassium. **Side-effects:**

PRESCRIBING ADVANCE

**Forms a stronger
to prevent**

**Prescribe it by name:
Gaviscon Advance 10ml**

GAVISCON ADVANCE

**The most advanced way to
prescribe Gaviscon**

Very rare hypersensitivity reactions. **Basic NHS Cost:** 500ml liquid £5.40.
Marketing Authorisation: 0063/0097. **Supply Classification:** Pharmacy Medicinal
Product. **Holder of Marketing Authorisation:** Reckitt & Colman Products Limited.

Dansom Lane, Hull, HU8 7DS. Gaviscon Advance and the sword and circle symbol
are trademarks. **Date of preparation:** December 1996. **References:** 1,2. Data on
file. Reckitt & Colman Products Limited. 3. Liquid Gaviscon 500ml (25-50 doses at

10-20ml qds) basic NHS price £2.70; Gaviscon Advance 500ml (50-100 doses at 5-
10ml qds) basic NHS price £5.40. 4. Data on file, Reckitt & Colman Products Limited.



Reckitt & Colman Products Limited

STAY HEALED[†]



NOW APPROVED IN MAINTENANCE

15mg ZOTON^{*}

Lansoprazole

[†] Up to 87% remission rate in reflux oesophagitis after 1 year. (Range 69-87%)¹⁻⁵

ZOTON^{*} Abbreviated Prescribing Information

Presentation: Two tone lilac/purple capsules containing lansoprazole 30 mg. Opaque yellow capsules containing lansoprazole 15 mg. **Indications:** Healing and maintenance of gastro-oesophageal reflux disease (GORD) or duodenal ulcer. Healing of benign gastric ulcer. Effective for benign peptic lesions including reflux oesophagitis unresponsive to H₂ receptor antagonists. Eradication of *Helicobacter pylori* (*H. pylori*) in patients with duodenal ulcer or gastritis. **Dosage and Administration:** Duodenal ulcer: 30 mg for 4 weeks, then 15 mg for maintenance dose. GORD: 30 mg daily for 4-8 weeks, then 15 mg or 30 mg for maintenance dose. Benign gastric ulcer: 30 mg daily for 8 weeks. *H. pylori* eradication: 30 mg twice daily plus two of the following antibiotics for 7 days: clarithromycin 250 mg twice daily, amoxicillin 1 g twice daily or metronidazole 400 mg twice daily. Swallow capsules whole. No dosage adjustment is necessary in the elderly, or the renally or hepatically impaired. There is no experience with Zoton in children. **Contra-indications:** None known. **Precautions:** Exclude the possibility of malignancy when gastric ulcer is

suspected. When using in combination with antibiotics, refer to the prescribing information of the respective antibiotics. **Pregnancy and Lactation:** Avoid in pregnancy. Avoid during breast feeding unless essential. **Interactions:** Interactions with drugs metabolised by the liver are possible. Apply caution when used concomitantly with oral contraceptives, phenytoin, theophylline or warfarin. Antacids should not be taken within an hour of Zoton. **Side Effects:** Generally mild and transient, including gastro-intestinal disturbances, headache, dizziness, malaise, dry or sore mouth or throat, fatigue, rashes, urticaria, pruritis and alterations in liver function test values. A few cases of arthralgia, myalgia, peripheral oedema, depression, haematological changes, bruising, purpura, petechiae, jaundice, hepatitis, paraesthesia or blurred vision have been reported. **Legal Category:** POM **Package Quantities:** 30 mg capsules: Blister packs of 56, 28, 14 and 7 (hospital starter pack) capsules. 15 mg capsules: Blister packs of 56 and 28 capsules. **Product Licence Number:** 30 mg capsules: PL 0095/0264 15 mg capsules: PL 0095/0302 **Cost:** 30 mg capsules: 7 £9.09 (hospital starter pack) 14 £16.68 28 £33.36 56 £66.72 15 mg capsules: 28

£18.95 56 £37.90 Full prescribing information is available on request. **Name and Address of Licence Holder:** Cyanamid of Great Britain Ltd, Fareham Road, Gosport, Hampshire, PO13 0AS. **REFERENCES:** 1. Gough, A.L. et al, *Aliment Pharmacol Ther*, 1996, **10**, 529-539 2. Hatlebakk, J.G., and Berstad, A., *Gastroenterol*, 1995, **108** (4), A111 (102909) 3. Poynard, T. et al, *Gastroenterol*, 1995, **108** (4), A195 (102907) 4. Robinson, M., *Ann Intern Med*, 1996, **126**, 859-867 5. Baldi, F., *Gastroenterol*, 1996, **110** (4) Suppl A55 (107136), and Data on file, Lederle Laboratories (105806). * Trademark of Takeda Chemical Industries Ltd. Date of preparation: August 1996



Under Licence agreement with Takeda Chemical Industries Ltd, Japan.



Further information can be obtained from: Wyeth Laboratories, Huntercombe Lane South, Taplow, Maidenhead, Berks SL6 0PH

Wyeth

TO Deliver

MULTIPLE CHOICE SOLUTION

EASY AND EASY TO USE

For ease of use for patients and health professionals.

COMPREHENSIVE DOSE RANGE


3 MU, 4.5 MU, 6 MU, 9 MU single dose pre-filled syringes.

ISA FREE

No risk of viral contamination.

SUPPORT

Patient education materials and further information about the complete Roferon-A range are available via Freephone Roferon-A: 0800 387189.



NOW AVAILABLE IN A RANGE OF PRE-FILLED SYRINGES FOR EASE OF DELIVERY

Interferon alfa-2a (rbe)

BRIEF PRESCRIBING INFORMATION.

INDICATIONS: Hairy cell leukaemia; AIDS-related Kaposi's sarcoma without prior opportunistic infection (as single agent); chronic active hepatitis B; Piv positive chronic myelogenous leukaemia (adults >18 years); recurrent or metastatic renal cell carcinoma; refractory, progressive, cutaneous T-cell lymphoma; chronic hepatitis C; Follicular non-Hodgkin's lymphoma. **DOSAGE:** Modify dose according to toxicity or pre-existing reduced bone marrow function. **Adults: Hairy cell leukaemia** - Induction with 3 million IU daily IM or SC for 16-24 weeks; maintenance with 3 million IU three times per week. **AIDS-related Kaposi's sarcoma** - Escalation from 3 million IU daily, SC or IM, to 18-36 million IU daily over 12 weeks, then maintenance with maximum tolerated dose (to maximum of 36 million IU) three times per week. Recurrence of Kaposi's sarcoma lesions possible on stopping treatment. **Chronic active hepatitis B** - Usually 2.5-5.0 million IU/m² SC for 4-6 months; escalation permitted in absence of response. Efficacy not shown in hepatitis B with HIV co-infection. **Chronic myelogenous leukaemia** - Escalation from 3 million IU daily to 9 million IU daily, SC or IM, over 12 weeks. Continue to complete haematological response, or maximum 18 months treatment, in responders. Complete haematological responders should continue with 9 million IU, daily (if tolerated) or three times per week, to achieve cytogenic response. **Recurrent or metastatic renal cell carcinoma** - Escalation from 3 up to maximum 36 million IU daily, IM, over 10 to 12 weeks (SC administration permitted for doses up to 18 million IU). Maintenance with 18-36 million IU three times per week. **Refractory, progressive, cutaneous T-cell lymphoma** - Escalation from 3 million IU to 18 million IU daily IM or SC for total 12 weeks, then maintenance with maximum tolerated dose (up to 18 MU) three times per week for at least 8 weeks to determine response, and at least 12 months in responders. **Chronic hepatitis C** - Induction with 6 million IU three times weekly IM or SC for 3 months followed by maintenance with 3 million IU three times weekly for 3 months in responders (normalised ALT). **Advanced follicular non-Hodgkin's lymphoma** - With conventional 'CHOP-like' chemotherapy, e.g. 6 MU/m² days 22-26 per 28-day cycle. **ADMINISTRATION:** Vials - For subcutaneous or deep intramuscular injection. **Pre-filled Syringes** - For subcutaneous injection. Vary site for repeat injections. **CONTRA-INDICATIONS:** Hypersensitivity to interferons or ROFERON-A excipients; severe cardiac, renal, hepatic or myeloid disease; epilepsy and/or compromised CNS function. Chronic hepatitis with advanced, decompensated, liver cirrhosis;


recent immunosuppressive therapy (including short term "steroid withdrawal"); CMV. Immediate candidates for allogeneic bone marrow transplantation. **PRECAUTIONS:** Use under specialist supervision. Monitor renal, hepatic and myeloid function closely if pre-existing mild to moderate impairment. Neuropsychiatric monitoring; suicidal behaviour has been rarely observed (discontinuation recommended). Extreme caution in severe myelosuppression (monitor complete blood count), and transplant patients on immunosuppressants. Possible exacerbation or provocation of psoriasis. Possible impairment of driving, machine operation etc. Safety and efficacy in children has not been established. Auto-antibodies have been reported and autoimmune phenomena such as vasculitis, arthritis, haemolytic anaemia, thyroid dysfunction and lupus erythematosus have been rarely observed. **SPECIAL PRECAUTIONS FOR THE 18MU/0.5ML MULTI-DOSE VIAL:** Each vial to be used by a single patient, using aseptic techniques. A new needle and plastic syringe should be used for each dose, the top of the vial sterilised before each withdrawal. After opening, the contents are stable for 30 days at 5°C, vials should be dated after withdrawal of the first dose. Single dose vials NOT to be used for multiple dosing. **DRUG INTERACTIONS:** CNS active drugs and those metabolised by oxidative enzymes. Additive toxicity with neuroleptics, haemostatics, or cardiotoxic agents. May reduce clearance of theophylline. **PREGNANCY:** Avoid (Use only where potential benefit outweighs risk to foetus). Contraception to be used in fertile males and females. Avoid in breast feeding. Known abortifacient in primates. **SIDE-EFFECTS AND ADVERSE REACTIONS:** General symptoms: influenza-like symptoms (respond to paracetamol). GI tract: anorexia and nausea. GI upset and rarely GI bleeds or reactivation of peptic ulcer. Liver function: Altered liver function tests; rare reports of hepatitis and liver failure. CNS symptoms: Uncommonly, dizziness, vertigo, visual disturbances, forgetfulness, depression, drowsiness, confusion, nervousness and sleep disturbances; rare reports of suicidal behaviour, idiopathic retinopathy, convulsions, severe somnolence and coma. Peripheral nervous system: Occasionally sensory and motor neuropathies. Cardiovascular & pulmonary: Transient BP fluctuations, oedema, epacoe, arrhythmias, palpitations and chest pain. Rarely, myocardial infarction, congestive cardiac failure, pulmonary oedema, pneumonia and cardiorespiratory arrest. Rarely coughing, mild dyspnoea. Skin, mucous membranes etc.: Rarely herpes labialis exacerbation, rash, pruritus, dryness, telangiectases and epistaxis; reversible alopecia. Renal: Rarely renal

impairment; electrolyte disturbances; proteinuria, interstitial nephritis; rare elevations in BUN, serum creatinine and uric acid. Haematopoietic: Transient leucopenia; thrombocytopenia; rarely decreased haemoglobin and haematocrit. Severe changes resolved by 7-10 days post-treatment. Other: Inconsequential hypocalcaemia; hyperglycaemia; injection site reaction; menstrual irregularities, in animals; development of neutralising antibodies. In patients with hepatitis C a trend for loss of response in responding patients who develop such antibodies has been seen, no other clinical sequelae clearly documented. **LEGAL CATEGORY:** POM. **PRESENTATIONS AND BASIC NHS COST:** **Pre-filled syringes:** 3 million IU interferon alfa-2a (rbe) in 0.5ml £16.96 4.5 million IU interferon alfa-2a (rbe) in 0.5ml £25.44 6 million IU interferon alfa-2a (rbe) in 0.5ml £33.92 9 million IU interferon alfa-2a (rbe) in 0.5ml £50.98 **Single dose vials:** 3 million IU interferon alfa-2a (rbe) in 1ml £16.96 4.5 million IU interferon alfa-2a (rbe) in 1ml £25.44 6 million IU interferon alfa-2a (rbe) in 1ml £33.92 9 million IU interferon alfa-2a (rbe) in 1ml £50.98 Each presentation includes a disposable syringe for IM or SC injections. **Multi-dose vial:** 18 million IU interferon alfa-2a (rbe) in 3 ml in packs of 3 vials £305.31 **PRODUCT LICENCE NUMBERS:** **Pre-filled Syringes:** PL 0031/0405 (3MU/0.5ml); PL 0031/0406 (4.5MU/0.5ml); PL 0031/0407 (6MU/0.5ml); PL 0031/0408 (9MU/0.5ml) **Vials:** PL 0031/0409 (3 MU/1ml); PL 0031/0411 (4.5 MU/1ml); PL 0031/0402 (6 MU/1ml); PL 0031/0403 (9 MU/1ml) PL 0031/0404 (18 MU/3ml multi-dose vial) **PRODUCT LICENCE HOLDER:** Roche Products Limited, PO Box 8, Welwyn Garden City, Herts., AL7 3HY. Full prescribing information available on request. ROFERON is a registered trademark. **DATE OF PREPARATION:** January 1997



This woman

HAS HEPATITIS C



Do you tell her

IT COULD BE FATAL?

85,000 people in the UK
have chronic HCV*



50,000 of them will
develop cirrhosis*



10,000 will develop
liver cancer*



Many will die
prematurely




She could be one of them



Viraferon is not a vaccine,
nor a miracle cure.
But should this patient
develop chronic HCV
it could save her life.

VIRAFERON
INTERFERON ALFA-2B (rbe)



Today, for the future

ABBREVIATED PRESCRIBING INFORMATION

Before prescribing Viraferon please refer to full Data sheet. **Presentation:** 10 million or 25 million IU/vial of Interferon Alfa-2b (rbe) in solution. **Uses:** Treatment of Chronic Active Hepatitis B; reduction of disease activity in Chronic Hepatitis C/Non-A, Non-B. **Dosage and Administration:** Chronic Active Hepatitis B: The recommended dosage is usually in the range of 2.5 million IU to 5.0 million IU/m² of body surface area administered subcutaneously three times per week for a period of four to six months. Chronic Hepatitis C/Non-A, Non-B: The recommended dose is 3 million IU administered three times a week. Most patients who respond demonstrate improvement in ALT levels within 12-16 weeks. In those patients, therapy should be continued with 3 million IU three times a week for up to 18 months. **Contraindications, Warnings, Precautions, etc.:** Contraindications: A history of hypersensitivity to recombinant Interferon Alfa-2b, or components of VIRAFERON Injection contraindicates its use; severe pre-existing cardiac disease, severe renal or hepatic dysfunction; epilepsy and/or compromised central nervous system function; chronic hepatitis with advanced decompensated cirrhosis of the liver; chronic hepatitis patients who are being or have been recently treated with immunosuppressive agents excluding short-term corticosteroid withdrawal. Autoimmune hepatitis or history of autoimmune disease, pre-existing thyroid disease not controlled by conventional therapy. **Warnings and Precautions:** Use with caution in patients with a history of pulmonary disease, diabetes mellitus, coagulation disorders or severe myelosuppression. Moderate to severe adverse experiences may require reduction of dosage or termination of VIRAFERON therapy. Patients with chronic Hepatitis B with evidence of decreasing hepatic synthetic function may be at increased risk of clinical decompensation if a flare of aminotransferases occurs during treatment. Patients with a recent history of cardiovascular events should be closely monitored as adverse cardiovascular events including hypotension and cardiac arrhythmias have been observed. Adequate hydration of patients should be maintained during treatment. Pulmonary infiltrates, pneumonitis and pneumonia, including fatality, have been observed rarely. Reversible CNS effects commonly manifested by confusion have been seen, usually at high doses. Infrequently, patients treated for chronic Hepatitis C/Non-A, Non-B developed thyroid abnormalities, either hypothyroid or hyperthyroid. VIRAFERON may exacerbate pre-existing psoriatic disease. Ocular adverse events have been reported. Concomitant narcotics or sedatives should be administered with caution. Patients taking xanthine derivatives should be monitored and dosage adjusted as necessary. No information is available on the use of interferon in human pregnancy, or its effect on human lactation. VIRAFERON should only be given if the benefits clearly outweigh the potential hazard to the foetus or nursing infant. **Side Effects:** Elevated liver function tests, reduction in white blood cells, granulocytes and platelet counts have been observed especially at higher doses. Retinal haemorrhages, cotton wool spots and retinal artery or vein obstruction have been observed rarely. The most common adverse effects are flu-like symptoms, leucopenia, thrombocytopenia and CNS effects, which are generally dose-related and reversible and can be ameliorated by dose adjustment. Flu-like symptoms can be alleviated by the use of paracetamol. **Package Quantities:** 10 million IU (2m² and 25 m² IU vial, 5ml per vial. **Trade Price:** Starter Pack - 10 Million IU (2m² pack containing 1 x 10M IU vial, £56.52) - 25 Million IU (5ml pack containing 1 x 25M IU vial, £141.30. **Multi-vial Packs:** 10 Million IU (2m² pack containing 3 x 10M IU vials, £169.56) - 25 Million IU (5ml pack containing 2 x 25M IU vials, £282.60. **Legal Category:** POM. **Product Licence Numbers:** PL 0201/0203-0204. Further information is available from the Product Licence Holder, Schering-Plough Ltd, Shire Park, Welwyn Garden City, Hertfordshire AL9 1TW. **References:** 1. Lau J, Williams R, The GB Specialist Forum, Medical Dialogue 1991; 334-144. 2. Hepatitis Information for General Practitioners British Liver Trust.

Dosage in hepatitis C:
3M IU
three times a week
for up to 18 months

Date of Preparation: January 1996

Schering-Plough

* Estimates based on current incidence and epidemiology of hepatitis C



Gold Medal, Atlanta Olympics 1996 (Coxless Pair)

OVER 90% H. PYLORI ERADICATION¹
OVER 90% PATIENT COMPLIANCE¹


Rx KLARICID 500MG B.D.

OMEPRAZOLE 20MG O.D.

AMOXYCILLIN 1G B.D. *for 10 days*

NEW TRIPLE THERAPY
KLARICID[®] 500
Clarithromycin

Prescribing information P1/14/002 Klaricid 500

Presentation: Yellow ovaloid film coated tablets containing 500mg of clarithromycin. Each tablet is engraved with  on one side. **Indications:** Klaricid in the presence of acid suppression effected by omeprazole is indicated for the eradication of H. pylori in patients with duodenal ulcers. **Dosage and Administration:** Adults: Dual therapy: clarithromycin 500mg t.d.s. for 14 days plus oral omeprazole 40mg o.d. The pivotal study was carried out with omeprazole 40mg o.d. for 28 days, whilst supportive studies were carried out with omeprazole 40mg o.d. for 14 days. Triple therapy: Klaricid (500mg) b.d. should be given with amoxycillin 1000mg twice daily and omeprazole 20mg daily for 10 days. See omeprazole and amoxycillin data sheet for further information on omeprazole dosing. **Contraindications, Warnings etc:** **Contraindications:** known hypersensitivity to macrolide drugs. Do not administer with any of the following: cisapride, pimozide, terfenadine, ergot derivatives. **Precautions:** Caution in adults with impaired hepatic

and renal function. Prolonged or repeated use of clarithromycin may result in an overgrowth of non-susceptible bacteria or fungi. If superinfection occurs, clarithromycin should be discontinued and appropriate therapy instituted. Caution in patients taking drugs metabolised by the cytochrome P450 system as there may be elevations in their serum levels. H. pylori organisms may develop resistance to clarithromycin in a small number of patients. **Interactions:** Potentiation of astemizole, theophylline, digoxin, warfarin and carbamazepine. Interaction of Klaricid tablets with simultaneously administered zidovudine in adults. No interaction with oral contraceptives. **Side-effects:** Klaricid is generally well tolerated. Side-effects include nausea, dyspepsia, vomiting, diarrhoea and rarely pseudomembranous colitis, abdominal pain, headache, taste perversion, reversible tongue discoloration, glossitis, stomatitis and oral monilia. Allergic reactions including anaphylaxis and Stevens-Johnson syndrome, and transient central nervous system side-effects have been reported. Hepatic dysfunction has

also been reported. There have been reports of hearing loss which is usually reversible on withdrawal of therapy. **Use in Pregnancy and Lactation:** The safety of Klaricid during pregnancy and breast feeding has not been established, and therefore if a patient becomes pregnant Klaricid should only be used if the benefits outweigh risks. Clarithromycin has been found in the milk of lactating animals and humans. **Overdose:** Should be treated with gastric lavage and supportive measures. **Legal Category:** POM. **Marketing Authorisation Number:** PL 0037/0254: 20 or 42 tablet calendar blister pack. **Basic NHS Price:** 500mg b.d. £3.21 per day; 500mg t.d.s. £4.82 per day.

Further information is available on request from Abbott Laboratories Ltd., Norden Road, Maidenhead, Berkshire SL6 4XE. Date of Preparation September 1996. Reference: 1. Data on file, Abbott Laboratories. PXXHP6227

ABBOTT
ANTIBIOTICS

Basic Upper Gastrointestinal Endoscopy

16th - 17th April 1997

Course Fee: £500

A two day basic endoscopy training course ideally suited for both medical and surgical trainees who wish to develop an interest in endoscopy. The course covers the basic skills and safety for upper GI endoscopy in tutorials and video presentations but also allows for "hands on" experience. Practical exercises of endoscopic manipulation using life like models and live endoscopy with personal tuition for GMC registered participants. Experienced faculty.

In addition an optional third day providing more "hands on" experience and individual personal endoscopic tuition is available to a maximum of 6 participants.

(Optional extra day 18th April 1997 £300)

Course fee excludes accommodation but includes lunch and all course materials.



Contact: Mrs J Struthers
Surgical Skills Unit
Level 5, Ninewells Hospital and Medical School,
Dundee, DD1 9SY
Tel. 01382 645857 Fax 01382 646042

University
Of Dundee

"The University exists to promote higher education and research and is an equal opportunities employer"

SURGICAL SKILLS UNIT

Scientific Basis of
Health
Services

BMJ

ISBN 0 7271

science in care

day but the concept that the
d on scientific evidence is less
conferences, The Scientific Basis
ideas can be tested in research.

• Sharing the balance between
With contributions from
way to the future and
management of

day but the concept that the
d on scientific evidence is less
conferences, The Scientific Basis
ideas can be tested in research.

Available from: BMJ Publishing Group, PO Box 295, London WC1H 9TE,
medical booksellers or the BMJ bookshop in BMA House.
OR: Phone on our credit card hotline: 0171 383 6185/6245 or fax: 0171 383 6662
PRINT CLEARLY Please send me.....copy/ies of Scientific Basis of Health Services

Name

Address

Postcode.....Membership No:


☐ Cheque enclosed (made payable to British Medical Journal) £.....
☐ Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No Expires

Signature

Order your copy today

UEGW BIRMINGHAM '97



**6th UNITED
EUROPEAN
GASTROENTEROLOGY
WEEK**

**18 - 23 October 1997
ICC, Birmingham, UK**

KEY DATES

March 1997

23 May 1997

15 August 1997

18-23 October 1997

Final Announcement & Call for Abstracts available

Deadline for submission of Abstract Forms

Last date for reduced registration fees

6th UEGW

International Faculty of 250

including Blaser, Brandtzaeg, Cotton, Furness, Kimura, Malagelada, Manns, Meyer, Pichlmayer, Sansonetti, Siewert, Tytgat, Vane, Watanabe, Wright and Wu.

Core Meeting – 8 Parallel Sessions

20 State-of-the-Art Lectures

including Future Endoscopy, Laparoscopic Surgery, TIPSS, H. pylori, Apoptosis, The Cell Cycle, Liver Fibrogenesis, 100 Years of Aspirin.

40 Topic Symposia – Basic Science, Clinical, Endoscopy.

4 Postgraduate Courses

Case orientated 'Evidence Based Gastroenterology'
Live Interactive Teaching of New Endoscopic Techniques
Liver Transplantation
Advances in Paediatric Gastroenterology and Nutrition

6 Industry-sponsored Satellite Meetings

Debates and Video Demonstrations
Daily CPC

Conference Reports

Free Papers, Posters and Poster Discussions

Biomedical Exhibition

For further information: 6th UEGW,
Concorde Services Ltd, 10 Wendell Road, London W12 9RT, UK
Tel: +44 181 743 3106 Fax: +44 181 743 1010

Taking charge of clinical risk...

CLINICAL RISK MANAGEMENT



BMJ

Edited by **CHARLES VINCENT**

Risk management has become a major issue in health care, aimed at reducing the probability of patients being harmed during treatment and minimising the subsequent consequences. This timely book is a unique source of reference for managers and clinicians keen to develop effective risk management, containing:

- Practical advice on implementation, the underlying principles, and recognising potential risks
- Chapters on the clinical applications in various specialties, including anaesthesia, obstetrics, paediatrics, and psychiatry
- Contributions from leaders in the field from the UK and USA
- All the information needed to investigate complaints, deal with claims in the optimum way, and reduce the impact of litigation

The definitive guide to improving the quality of care for your patients

Order your copy now

ISBN 0 7279 0947 9 588 pages January 1996
UK £34.95; Overseas £38.00 BMA members £32.95; £36.00

BMJ
Publishing
Group

...and other management concerns

Quality and Safety in Anaesthesia

Edited by Jonathan Secker Walker

"It is satisfying to find a text that states what quality in anaesthetic practice is really about."

Dr J. J. Thompson

ISBN 0 7279 0828 6


192 pages

UK £16.95;

Overseas £19.00

(BMA members

£15.95; £18.00)



Outcomes into Clinical Practice


Edited by Tony Delamothé

A ground-breaking book on outcomes research, focusing on the opportunities to improve clinical effectiveness and set standards for good practice.

ISBN 0 7279 0888 X

169 pages UK £17.95; Overseas £20.00

(BMA members £16.95; £19.00)



Rationing in Action

Expert advice on the implications of rationing to health providers and their patients.


ISBN 0 7279 0813 8 160 pages

UK £10.95;

Overseas £13.00

(BMA members

£9.95; £12.00)



Management for Doctors

Edited by Jenny Simpson and Richard Smith

"An insightful and inspiring guide for any doctor who wants to know and understand more about NHS management."


Dr J. J. Thompson

Dr J. J. Thompson

ISBN 0 7279 0858 8

200 pages UK £12.95; Overseas £15.00

(BMA members £11.95; £14.00)



ORDER FORM

Available from: **BMJ Publishing Group, P.O. Box 295, London WC1H 9TE** (Tel: 0171 383 6185/6245), medical booksellers or the **BMJ bookshop in BMA House**

Please send me

- ☐ copy/ies of **Clinical Risk Management**
- ☐ copy/ies of **Quality and Safety in Anaesthesia**
- ☐ copy/ies of **Outcomes into Clinical Practice**
- ☐ copy/ies of **Rationing in Action**
- ☐ copy/ies of **Management for Doctors**

BMA Membership No. _____

Name _____

(Print clearly)

Address _____

_____ **Postcode** _____

Cheque enclosed (made payable to British Medical Journal) £ _____

Debit my American Express/Visa/Mastercard

Card No. _____ **Exp** _____

Signature _____

☐ Please send me a **BMJ Publishing Group Catalogue**

Health care: the way ahead

Controversies in Health Care Policies: Challenges to Practice

Edited by Marshall Marinker

Can health policy ever be completely right?

This book explores how to get it right in six of today's most important issues: rational prescribing; primary care following Tomlinson; public access to medical information; the meaning of aging; medical practice variation; and risk in medicine.

CONTROVERSIES in HEALTH CARE POLICIES

Challenges to Practice

EDITED BY
MARSHALL MARINKER

BMJ
Publishing Group

- Essential reading for all involved in making and implementing health care policies.

- Documents the work of six think tanks of clinical experts, GPs, managers, and patient representatives

- Includes input from the Kings Fund, NAHAT, Age Concern, RCGP, National Medical Adviser Support Centre, Social Market Foundation

- Offers innovative and realistic ideas for the way forward

ISBN 0 7279 0894 4 144 pages

November 1994

UK £12.95; Overseas £15.00

(BMA members £11.95; £14.00)

Outcomes into Clinical Practice

Edited by Tony Delamothe

**Why do outcomes research?
How should it be done?**

These crucial questions are addressed in this ground breaking book, based on the conference held by the BMJ, BMA, and UK Clearing House for Information on the Assessment of Health Outcomes. In it, experts in the field cover a wide range of topics including acute care; cost effectiveness; death rates; health gains; and general practice.

- Shows how information on outcomes can be used to improve care

- Gives examples of outcomes research at its best

- Looks at the subject from all perspectives in the health service


- Provides an ideal starting point for all members of clinical teams, both in hospitals and general practice, and is invaluable for health care purchasers and clinical audit officers.

ISBN 0 7279 0888 X 184 pages

November 1994

UK £17.95; Overseas £20.00

(BMA members £16.95; £19.00)



Edited by TONY DELAMOTHE

BMJ
Publishing Group

Also available

A Manual for Assessing Health Practices and Designing Practice Policies: the explicit approach

By David M Eddy

Published by the American College of Physicians

ISBN 0 943126 18 5 100 pages 1992 UK £19.95; Overseas £21.00 (BMA members £17.95; £19.00)

ORDER FORM

Available from: BMJ Publishing Group, P.O. Box 295, London WC1H 9TE (Tel: 0171 383 6185/6245),
medical booksellers or the BMJ bookshop in BMA House

Please send me the following books

Name _____
(Print Clearly)

Address _____

Postcode _____

BMA Membership No. _____

Cheque enclosed (made payable to British Medical Journal) £ _____
Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No. _____ Exp. _____

Signature _____

☐ Please send me a BMJ PUBLISHING GROUP CATALOGUE

BMJ
Publishing
Group

"The proton pump inhibitor
that is setting the standard for
clinical safety?"



PRECISELY.



PANTOPRAZOLE*

A new level of precision in acid control

Since indications may vary from country to country, please consult your local prescribing information.

Abbreviated Prescribing Information: Pantoprazole Byk Gulden. See local prescribing information for full details. **Indications and dosage:** Duodenal ulcer 40 mg Pantoprazole once daily for 2-4 weeks. Gastric ulcer and moderate and severe reflux oesophagitis 40 mg Pantoprazole once daily for 4-8 weeks. 40 mg Pantoprazole once daily is recommended. If needed, the dose can be increased to 80 mg. **Precautions:** When gastric ulcer is suspected, the possibility of malignancy should be excluded before treatment is initiated. Use during pregnancy and lactation should be avoided unless considered essential. Interactions with other drugs metabolised by the Cytochrome-P-450-System cannot be excluded. In a series of studies specific with such drugs (Diazepam, Warfarin, Theophylline, Phenytoin, Digoxin and one oral contraceptive) no interactions were provable. Alteration of absorption of substances with pH-dependent absorption should be considered. Pantoprazole should not be used in cases of known hypersensitivity to one of its constituents or severely impaired liver function. **Side effects:** headache, diarrhoea, rarely nausea, upper abdominal pain, flatulence, skin rashes, pruritus, dizziness. Edema, fever, the onset of depression and disturbances in vision (blurred vision) were reported in individual cases. **Presentation*:** Pantoprazole 40 mg tablets each containing 45.1 mg Pantoprazole-Sodium-Sesquihydrate.

For further information please contact Byk Gulden, Byk Gulden-Straße 2, D-78467 Konstanz, Germany, or the local subsidiary.



Byk Gulden